中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

24 records (took 0.028 seconds)

    Apparatus and method for monitoring network resources
    11.
    发明申请
    Apparatus and method for monitoring network resources 审中-公开
    用于监控网络资源的装置和方法

    公开(公告)号：US20060177004A1

    公开(公告)日：2006-08-10

    申请号：US11043396

    申请日：2005-01-26

    Applicant: Adrian Gilbert

    Inventor： Adrian Gilbert

    IPC: H04M11/04

    CPC classification number: H04L43/12 ,  H04L41/00 ,  H04L63/1408

    Abstract: A method and apparatus for monitoring network resources is disclosed. Code for use in instructing components in a network monitoring system is provided. The components include at least one data gathering for gathering operation data from a monitor network constituent. A main computer system has a database for storing the operation data. A data forwarder permits communication of the operation data from the data gather to the computer system. The computer system is remotely located from the data gatherer. The code includes information for creating custom tables in the database to hold the operation data. Information permits the data gatherer to selectively gather the operation data from other possible data that is capable of being gathered from the monitor constituent.

    Abstract translation: 公开了一种用于监控网络资源的方法和装置。 提供了用于指示网络监控系统中组件的代码。 这些组件包括用于从监视器网络组件收集操作数据的至少一个数据收集。 主计算机系统具有用于存储操作数据的数据库。 数据转发器允许从数据收集到计算机系统的操作数据的通信。 计算机系统远离数据采集器。 代码包括在数据库中创建自定义表以保存操作数据的信息。 信息允许数据采集器从能够从监视器组件收集的其他可能数据中选择性地收集操作数据。

    Parenteral formulations of peptides for the treatment of systemic lupus erythematosus
    12.
    发明申请
    Parenteral formulations of peptides for the treatment of systemic lupus erythematosus 审中-公开
    用于治疗系统性红斑狼疮的肽的肠胃外制剂

    公开(公告)号：US20050008634A1

    公开(公告)日：2005-01-13

    申请号：US10758397

    申请日：2004-01-14

    Applicant: Sharon Cohen-Vered ,  Esmira Naftali ,  Vera Weinstein ,  Adrian Gilbert ,  Ety Klinger

    Inventor： Sharon Cohen-Vered ,  Esmira Naftali ,  Vera Weinstein ,  Adrian Gilbert ,  Ety Klinger

    IPC: A61K20060101 ,  A61K6/00 ,  A61K9/00 ,  A61K9/19 ,  A61K38/00 ,  A61K38/08 ,  A61K38/10 ,  A61K38/16 ,  A61K38/17 ,  A61K39/395 ,  A61K47/40 ,  A61P37/00 ,  C07K7/06 ,  C07K7/08 ,  C07K14/47

    CPC classification number: C07K7/06 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/1709 ,  C07K7/08 ,  C07K14/4713 ,  C07K2319/00

    Abstract: The subject invention provides a pharmaceutical composition comprising: an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a) a peptide comprising at least 12 and at most 30 consecutive amino acids having a sequence corresponding to (i) a sequence of amino acids found within a complementarity-determining region (CDR) of a heavy or a light chain of a human monoclonal anti-DNA 16/6 Id antibody, or (ii) a sequence of amino acids found within a complementarity-determining region (CDR) of a heavy or a light chain of a pathogenic anti-DNA monoclonal antibody that induces a systemic lupus erythematosus (SLE)-like disease response in mice, or b) a peptide comprising consecutive amino acids having the sequence shown by any of SEQ ID NOS. 8-17, or c) a peptide comprising consecutive amino acids having a sequence of any of a) and b), or at least two of the sequences in (a) (i), (a) (ii) and (b)(i) through (b)(x), or d) a peptide comprising consecutive amino acids having a sequence comprising at least two identical sequences included in (a) (i), (a) (ii) and (b) (i) through (b) (x); and a solubility enhancer, wherein both the peptide and the solubility enhancer are dissolved in the aqueous carrier; and wherein the composition has a pH between 4 and 9, and a method of alleviating symptoms of SLE in a human by administering an effective amount of the composition.

    Abstract translation: 本发明提供一种药物组合物，其包含：水性载体; 从0.1mg / ml至20mg / ml组合物的药学上可接受的盐a）包含至少12个和至多30个连续氨基酸的肽，其具有对应于（i）在 人单克隆抗-DNA 16/6 Id抗体的重链或轻链的互补决定区（CDR），或（ii）在重链或重链或重链的互补决定区（CDR）内存在的氨基酸序列， 致病性抗DNA单克隆抗体的轻链，其在小鼠中诱导系统性红斑狼疮（SLE）样疾病反应，或b）包含具有SEQ ID NOS中任一个所示序列的连续氨基酸的肽。 （a）（i），（a）（ii）和（b）中的至少两个序列的连续氨基酸的肽包含a）和b）中任一个的序列，或c） （i）至（b）（x）所述的肽，或d）包含连续氨基酸的肽，其具有包含（a）（i），（a）（ii）和（b） ）通过（b）（x）; 和溶解度增强剂，其中肽和溶解度增强剂都溶解在水性载体中; 并且其中所述组合物的pH为4至9，以及通过施用有效量的组合物来减轻人类SLE症状的方法。

    PARENTERAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF SYSTEMATIC LUPUS ERYTHEMATOSUS
    15.
    发明申请
    PARENTERAL FORMULATIONS OF PEPTIDES FOR THE TREATMENT OF SYSTEMATIC LUPUS ERYTHEMATOSUS 审中-公开
    用于治疗系统性红斑狼疮的肽的配体配方

    公开(公告)号：US20130023485A1

    公开(公告)日：2013-01-24

    申请号：US13453979

    申请日：2012-04-23

    Applicant: Sharon Cohen-Vered ,  Esmira Naftali ,  Vera Weinstein ,  Adrian Gilbert ,  Ety Klinger

    Inventor： Sharon Cohen-Vered ,  Esmira Naftali ,  Vera Weinstein ,  Adrian Gilbert ,  Ety Klinger

    IPC: A61K38/10 ,  A61K38/16 ,  A61P19/04 ,  A61K38/08

    CPC classification number: C07K7/06 ,  A61K9/0019 ,  A61K9/19 ,  A61K38/1709 ,  C07K7/08 ,  C07K14/4713 ,  C07K2319/00

    Abstract: The subject invention provides a pharmaceutical composition comprising: an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of a pharmaceutically acceptable salt of a) a peptide comprising at least 12 and at most 30 consecutive amino acids, b) a peptide comprising consecutive amino acids having the sequence shown by any of SEQ ID NOS. 8-17, c) a peptide comprising consecutive amino acids having a sequence of any of a) and b), or at least two sequences in (a), or d) a peptide comprising consecutive amino acids having a sequence comprising at least two identical sequences included in (a); and a solubility enhancer; and wherein the composition has a pH between 4 and 9, and a method of alleviating symptoms of SLE in a human by administering an effective amount of the composition.

    Abstract translation: 本发明提供一种药物组合物，其包含：水性载体; 从0.1mg / ml至20mg / ml的药学上可接受的盐a）包含至少12个和至多30个连续氨基酸的肽，b）包含具有SEQ ID NOS中任一个所示序列的连续氨基酸的肽 。 8-17，c）包含连续氨基酸的肽，其具有a）和b）中任一个的序列，或（a）中的至少两个序列，或d）包含连续氨基酸的肽，所述连续氨基酸具有包含至少两个 （a）中包含的相同序列; 和溶解度增强剂; 并且其中所述组合物的pH为4至9，以及通过施用有效量的组合物来减轻人类SLE症状的方法。

    RASAGILINE ORALLY DISINTEGRATING COMPOSITIONS
    16.
    发明申请
    RASAGILINE ORALLY DISINTEGRATING COMPOSITIONS 审中-公开

    公开(公告)号：US20120238636A1

    公开(公告)日：2012-09-20

    申请号：US13279100

    申请日：2011-10-21

    Applicant: Shulamit Patashnik ,  Daniella Licht ,  Adrian Gilbert

    Inventor： Shulamit Patashnik ,  Daniella Licht ,  Adrian Gilbert

    IPC: A61K31/135 ,  A61P25/16

    CPC classification number: A61K31/135 ,  A61K31/136

    Abstract: This invention provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, and particles having a non-filamentous microstructure of at least two sugar alcohols. This invention also provides a solid pharmaceutical composition comprising rasagiline or a pharmaceutically acceptable salt of rasagiline, a mixture of a disintegrant, a flow agent and particles having a non-filamentous microstructure of at least two sugar alcohols, a supplemental sugar alcohol, a supplemental flow agent, and a supplemental disintegrant. This invention further provides a method of treating a subject afflicted with Parkinson's disease comprising administering to the subject a therapeutically effective amount of the solid pharmaceutical composition, thereby treating the subject. Finally, this invention provides a process of making such solid pharmaceutical compositions.

    Abstract translation: 本发明提供了一种固体药物组合物，其包含雷沙吉兰或雷沙吉兰的药学上可接受的盐，以及具有至少两种糖醇的非丝状微结构的颗粒。 本发明还提供一种固体药物组合物，其包含雷沙吉兰或雷沙吉兰的药学上可接受的盐，崩解剂，流动剂和具有至少两种糖醇的非丝状微结构的颗粒的混合物，补充糖醇，补充流 代理和补充崩解剂。 本发明还提供了治疗患有帕金森病的受试者的方法，其包括向受试者施用治疗有效量的固体药物组合物，从而治疗受试者。 最后，本发明提供制备这种固体药物组合物的方法。

    Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus
    19.
    发明授权
    Parenteral formulations of a peptide for the treatment of systemic lupus erythematosus 有权
    用于治疗系统性红斑狼疮的肽的肠胃外制剂

    公开(公告)号：US07294687B2

    公开(公告)日：2007-11-13

    申请号：US10758572

    申请日：2004-01-14

    Applicant: Sharon Cohen-Vered ,  Esmira Naftali ,  Vera Weinstein ,  Adrian Gilbert ,  Ety Klinger

    Inventor： Sharon Cohen-Vered ,  Esmira Naftali ,  Vera Weinstein ,  Adrian Gilbert ,  Ety Klinger

    IPC: A61K38/00 ,  A61K31/74

    CPC classification number: B82Y5/00 ,  A61K9/0019 ,  A61K9/19 ,  A61K31/724 ,  A61K38/10 ,  A61K47/6951 ,  A61K2300/00

    Abstract: The subject invention provides a pharmaceutical composition comprising an aqueous carrier; from 0.1 mg/ml to 20 mg/ml of the composition of a pharmaceutically acceptable salt of a peptide having the structural formula NH2-Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly-COOH; and a substituted β-cyclodextrin in an amount effective to dissolve the peptide in the aqueous carrier, wherein the composition has a pH between 4 and 9, a process for preparation, and a method of alleviating symptoms of systemic lupus erythematosus (SLE) in a human subject comprising administering to the human subject the pharmaceutical composition.

    Abstract translation: 本发明提供包含水性载体的药物组合物; 从0.1mg / ml至20mg / ml组合物中具有结构式<βin-line-formula description =“In-line Formulas”end =“lead”？> 的药学上可接受的盐 NH 2 -Gly Tyr Tyr Trp Ser Trp Ile Arg Gln Pro Pro Gly Lys Gly Glu Glu Trp Ile Gly- COOH ; <βin-line-formula 描述=“内联式”末端=“尾”→和有效溶解该载体中的肽的量的取代的β-环糊精，其中该组合物的pH为4至9，制备方法， 以及减轻人受试者系统性红斑狼疮（SLE）症状的方法，包括向人受试者施用药物组合物。

Patent Agency Ranking